Young researchers working in Europe are invited to apply for the Eppendorf Award for Young European Investigators.
Researchers who are less than 35 have until 15 January 2012 to apply.
The award, inaugurated in 1995, acknowledges outstanding contributions to biomedical research in Europe based on methods of molecular biology, including novel analytical concepts.
An independent expert committee chaired by Kai Simons of the Max Planck Institute for Molecular Cell Biology and Genetics, in Dresden, Germany, will choose the winner.
The successful entrant will receive €15,000 in prize money and an invitation to the prize-giving ceremony at the EMBL Advanced Training Centre in Heidelberg, Germany on 9 May 2012.
In addition, he/she will be invited to Eppendorf in Hamburg and coverage of his/her work will be published in Nature magazine and in a podcast.
The official registration portal is at www.eppendorf.com/award/application. Only online registrations will be accepted.
Full details on the Eppendorf Award, the selection criteria and past award winners, are available at www.eppendorf.com/award.
Eppendorf Award for Young European Investigators opens for entry
Deadline is 15 January 2012
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development
AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment
AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy